Journal of veterinary internal medicine · 2026
Targeted proteomic analyses during combined angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist administration (CARDALIS®) in healthy dogs.
СтатьяRandomized Controlled Trial, VeterinaryНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ward Jessica L, Goodman Jessica, Blondel Thomas, Zdyrski Christopher, Manson Elizabeth, Merodio Maria, Lamers Ryan P, Allenspach Karin, Guillot Emilie, Mochel Jonathan P
Аннотация
BACKGROUND: The effects of renin-angiotensin-aldosterone system (RAAS) inhibitors on proteomic biomarkers of cardiovascular disease in dogs remain poorly characterized.
HYPOTHESIS/OBJECTIVES: To evaluate the effect of RAAS activation and treatment with a combination of benazepril and spironolactone on circulating proteomic biomarkers in healthy dogs.
ANIMALS: Eighteen healthy beagle dogs.
METHODS: Prospective experimental study. Dogs were fed a low-sodium diet to induce RAAS activation and randomly assigned to 1 of 3 dosing regimens for 14 days: (1) benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q24h (label dose); (2) benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q12h; or (3) benazepril 0.5 mg/kg + spironolactone 4 mg/kg PO q12h. Plasma samples were collected at multiple time points, and the concentrations of 177 unique proteins were quantified using multiplexed proximity extension assay technology via the Olink Target 96 Inflammation and Cardiovascular II panels. Differences between sampling days and groups were assessed using linear mixed models.
RESULTS: Renin-angiotensin-aldosterone system activation was associated with downregulation of proteins associated with cardioprotection, adaptive immunity, and tissue repair (eg, ACE2, FGF-5, CCL4, and MMP-10; P < .05 for all comparisons). Treatment with benazepril and spironolactone led to upregulation of adaptive immune proteins (eg, CCL4, TSLP) and proteins with cardioprotective functions (eg, ACE2). Dose-related differences were observed for a subset of biomarkers.
CONCLUSIONS AND CLINICAL IMPORTANCE: In this experimental model of RAAS activation, benazepril/spironolactone combination therapy exerts effects on markers of inflammation and fibrosis in dogs.
HYPOTHESIS/OBJECTIVES: To evaluate the effect of RAAS activation and treatment with a combination of benazepril and spironolactone on circulating proteomic biomarkers in healthy dogs.
ANIMALS: Eighteen healthy beagle dogs.
METHODS: Prospective experimental study. Dogs were fed a low-sodium diet to induce RAAS activation and randomly assigned to 1 of 3 dosing regimens for 14 days: (1) benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q24h (label dose); (2) benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q12h; or (3) benazepril 0.5 mg/kg + spironolactone 4 mg/kg PO q12h. Plasma samples were collected at multiple time points, and the concentrations of 177 unique proteins were quantified using multiplexed proximity extension assay technology via the Olink Target 96 Inflammation and Cardiovascular II panels. Differences between sampling days and groups were assessed using linear mixed models.
RESULTS: Renin-angiotensin-aldosterone system activation was associated with downregulation of proteins associated with cardioprotection, adaptive immunity, and tissue repair (eg, ACE2, FGF-5, CCL4, and MMP-10; P < .05 for all comparisons). Treatment with benazepril and spironolactone led to upregulation of adaptive immune proteins (eg, CCL4, TSLP) and proteins with cardioprotective functions (eg, ACE2). Dose-related differences were observed for a subset of biomarkers.
CONCLUSIONS AND CLINICAL IMPORTANCE: In this experimental model of RAAS activation, benazepril/spironolactone combination therapy exerts effects on markers of inflammation and fibrosis in dogs.